Table 2 WHO three essential antipsychotics and other drugs on the 'Essential' list (by drug class) to which they have been compared within randomized trials
From: Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs
| RCTs | Total number of people | Cochrane review | Reference | Up to date? | |
|---|---|---|---|---|---|
| Chlorpromazine | |||||
| vs anticonvulsant agents | 2 | 118 | ✗ | ||
| vs antidepressants | 12 | 732 | ✓ | [22, 23] | ✗ |
| vs antihypertensive agents | 8 | 286 | ✗ | ||
| vs antiparkinsonian agents | 3 | 80 | ✗ | ||
| vs antituberculosis agents | 1 | 25 | ✗ | ||
| vs barbiturates | 3 | 750 | ✗ | ||
| vs benzodiazepines | 9 | 457 | ✓ | [24, 25] | ✗ |
| vs mood stabilizers | 2 | 49 | ✓ | [26–28] | ✗ |
| vs opioid agonist | 1 | 340 | ✗ | ||
| vs opioid antagonist | 1 | 60 | ✗ | ||
| Fluphenazine decanoate | |||||
| vs antihypertensive agents | 1 | 17 | ✗ | ||
| vs antituberculosis agents | 1 | 55 | ✗ | ||
| Haloperidol | |||||
| vs antiarrhythmic agents | 2 | 30 | ✗ | ||
| vs antidepressants | 10 | 774 | ✓ | [22, 23] | ✗ |
| vs antidopaminergic agents | 4 | 146 | ✗ | ||
| vs antigout agents | 1 | 46 | ✗ | ||
| vs antihypertensive agents | 3 | 122 | ✗ | ||
| vs antineoplastic agents | 3 | 101 | ✗ | ||
| vs antiparkinsonian agents | 8 | 265 | ✗ | ||
| vs antiprogesterone agents | 1 | 80 | ✓ | [29] | ✗ |
| vs benzodiazepines | 35 | 4012 | ✓ | [24, 25] | ✗ |
| vs ethanol | 1 | 35 | ✗ | ||
| vs glucose | 1 | unclear | ✗ | ||
| vs mood stabilizers | 23 | 1648 | ✓ | [26–28] | ✗ |
| vs stimulant agents | 1 | 20 | ✗ | ||
